Molecular diagnosis of cystic fibrosis

Expert Review of Molecular Diagnostics

Volumn 2, Issue 3, 2002, Pages 240-256

  Shrimpton, Antony E ^a  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

CF carrier detection; Cystic fibrosis; Detection; Molecular diagnosis; Mutation

Indexed keywords

CYSTIC FIBROSIS; GENE FUNCTION; GENE MUTATION; GENE STRUCTURE; GENETIC SCREENING; HUMAN; MOLECULAR BIOLOGY; PHENOTYPIC VARIATION; QUALITY CONTROL; REVIEW;

EID: 0036086127     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737159.2.3.240     Document Type: Review

References (160)

1. Identification of the cystic fibrosis gene: Chromosome walking and jumping
2. Identification of the cytic fibrosis gene: Cloning and characterization of complementary DNA
3. Identification of the cystic fibrosis gene: Genetic analysis
4. Cystic Fibrosis
5. A novel cystic fibrosis gene mutation is common in patients with normal sweat chloride concentrations
6. Characterization of the cystic fibrosis transmembrane conductance regulator promoter region. Chromatin context and tissue-specificity
7. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis
8. Cystic fibrosis: Channel, catalytic and folding properties of the CFTR protein
9. Frontiers in research on cystic fibrosis: Understanding its molecular and chemical basis and relationship to the pathogenesis of the disease
10. Outwardly rectifying chloride channels and CF: A divorce and remarriage
11. Cystic fibrosis salt/fluid controversy: In the thick of it
12. Characterization of the internalization pathways for the cystic fibrosis transmembrane conductance regulator
13. Human B-Defensin-1 is a salt-senstive antibiotic in lung that is inactivated in cystic fibrosis
14. Prospects for gene therapy for cystic fibrosis
15. Update and review: Cystic Fibrosis
16. Cystic Fibrosis
17. Molecular diagnostics for cystic fibrosis
18. Cystic fibrosis molecular diagnosis, population screening and public policy
19. Human Genome Project and cystic fibrosis - A symbiotic relationship
20. Cystic fibrosis: Molecular approaches to diagnosis
21. Genetic analysis of DNA from single human oocytes: A model for preimplantation diagnosis of cystic fibrosis
22. Screening for cystic fibrosis carrier state
23. Laboratory standards and guidelines for population-based cystic fibrosis carrier screening
24. Cystic fibrosis population carrier screening: Here at last are we ready?
25. Genetic testing for cystic fibrosis
26. Geographic distribution and region origin of 272 cystic fibrosis mutations in European populations. The Biomed CF Mutation Analysis Consortium
27. Complete and rapid scanning of the cystic fibrosis transmemrane conductance regulator (CFTR) gene by denaturing high performance liquid chromatography (D-HPLC): Major implications for genetic counseling
28. Pitfall in the use of genotype analysis as the sole diagnostic criterion for cystic fibrosis
29. Structure-function analysis of a double-mutant cystic fibrosis transmembraine conductance regulator protein occurring in disorders related th cystic fibrosis
30. Screening for cystic fibrosis
31. Issues in implementing prenatal screening for cystic fibrosis: Results of a working conference
32. Couple screening for cystic fibrosis
33. Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth
34. Clinical features associated with a delayed diagnosis of cystic fibrosis
35. Newborn screening for cystic fibrosis
36. Growth status in children with cystic fibrosis based on the National Cystic Fibrosis Patient Registry data: Evaluation of various criteria used to identify malnutrition
37. Newborn screening for cystic fibrosis in Wisconsin: First application of population-based molecular genetics testing
38. Newborn screening for cystic fibrosis in Wisconsin: Comparison of biochemical and molecular methods
39. The M470V polymorphic locus affects CFTR
40. Variable deletion of exon 9 coding sequences in cystic fibrosis transmembrane conductance regulator gene mRNA transcripts in normal bronchial epithelium
41. Cystic Fibrosis carrier screening: Steps in the development of a mutation panel
42. Improved detection of cystic fibrosis mutations in the heterogeneous US population using an expanded, pan-ethnic mutation panel
43. Haplotype analysis of 94 cystic fibrosis mutations with seven polymorphic CFTR DNA markers
44. Cystic fibrosis-like disease unrelated to the cystic fibrosis transmembrane conductance regulator
45. Diversity of cystic fibrosis mutation-screening practices
46. Evaluation of CFTR gene mutation testing methods in 136 diagnostic laboratories: Report of a large European external quality assessment
47. Genetic testing and quality control in diagnostic laboratories
48. Recommendations for quality improvement in genetic testing for cystic fibrosis European concerted action on Cystic Fibrosis
49. Genetic testing for cystic fibrosis
50. Calculating posterior cystic fibrosis risk with echogenic bowel and one characterized cystic fibrosis mutation
51. Genotype and phenotype in cystic fibrosis
52. Genotype-phenotype correlations in cystic fibrosis
53. Genotypephenotype relationships in cystic fibrosis
54. Higher proportion of intact exon 9 CFTR mRNA in nasal epithelium compared with vas deferens
55. Frequency of carriers of two cystic fibrosis mutations in an apparently unaffected adult population
56. A mutation in CFTR produces different phenotypes depending on chromosomal background
57. Cystic fibrosis and infertility caused by congenital absense of the vas deferens and related clinical entities
58. Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes: The polymorphic (TG)n locus explains the partial penetrance of the T5 polymorphism as a disease mutation
59. Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA
60. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens
61. CFTR intron 8 poly-T tract length in men with congenital bilateral absence of the vas deferens
62. CFTR gene variant for patients with congenital absence of vas deferens
63. The diagnosis of cystic fibrosis: A consensus statement
64. Cystic fibrosis syndrome: A new paradigm for inherited disorders and implications for molecular diagnostics
65. Proportion of cystic fibrosis gene mutations not detected by routine testing in men with obstructive Azoospermia
66. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations
67. CFTR-mediated chloride permeability is regulated by Type III phosphodiesterases in airway epithelial cells
68. Use of protein repair therapy in the treatment of cystic fibrosis
69. Sodium 4-phenylbutyrate downregulates Hsc70: Implications for intracellular trafficking of ΔF508-CFTR
70. Direct activation of cystic fibrosis transmembrane conductance regulator channels by 8-cyclopentyl-1,3-dipropylxanthine (CPX) and 1,3-diallyl-8- cyclohexylxanthine (DAX)
71. Actions of genistein on cystic fibrosis transmembrane conductance regulator channel gating. Evidence for two binding sites with opposite effects
72. Therapies directed at the basic defect in cystic fibrosis
73. + transport in cystic fibrosis respiratory epithelia:abnormal basal rate and response to adenyl cyclase activation
74. Control of the poinflammatory state in cystic fibrosis lung epithelial cells by genes from the TNF-αR/NFκB pathway
75. The substituted benzimidazoione NS004 is an opener of the cystic fibrosis chloride channel
76. Strategies for correcting the dF508 CFTR protein-folding defect
77. Antagonists to the rescue
78. Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis
79. The molecular basis of disease variability among cystic fibrosis patients carrying the 3849+10kb C>T mutation
80. Diagnosis and treatment of cystic fibrosis
81. Etiology of CF: Knowns and unknowns
82. Alternative splicing in the first nucleotide binding fold of CFTR
83. A novel exon in the cystic fibrosis transmembrane conductance regulator gene activated by the nonsense mutation E92X in airway epithelial cells of patients with cystic fibrosis
84. Cellular and viral splicing factors can modify the splicing pattern of CFTR transcripts carrying splicing mutations
85. Antibiotics show promise as therapy for genetic disorders
86. Gene therapy for lung disease: Hype or hope?
87. Gene therapy: A primer for Radiologists
88. A cystic fibrosis tracheal gland cell line, CF-KM4 correction by adenovirus-mediated CFTR gene transfer
89. Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor
90. Incomplete rescue of cystic fibrosis transmembrane conductance regulator deficient mice by the human CFTR cDNA
91. Lung disease in mice with cystic fibrosis
92. Molecular Pathophysiology of cystic fibrosis based on the rescue knockout mouse model
93. Detection of a cystic fibrosis modifier for meconium ileus on human chromosome 19q13
94. Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis
95. Contribution of genetic factors other than CFTR to disease severity in cystic fibrosis
96. HLA class II polymorphism in cystic fibrosis. A possible modifier of pulmonary phenotype
97. Benign missense variations in the cystic fibrosis gene
98. Genotyping errors with the polymerase chain reaction
99. Experience of an academic reference laboratory using automation for analysis of cystic fibrosis mutations
100. The 4002Ato G polymorphism of the CFTR gene can interfere with the detection of the common 1282X and 3905insT mutations that occur within exon 20: Implications for carrier screening
101. Interference of P1290P polymorphism (4002A>G) in molecular detection of mucoviscidosis using the cystic fibrosis assay: An example of a diagnostic trap
102. Screening practices for mutations in the CFTR gene ABCC7
103. False-positive results of genetic testing in cystic fibrosis
104. Cystic fibrosis carrier frequencies in populations of African origin
105. Uniparental inheritance of microsatellite alleles of the cystic fibrosis gene (CFTR): Identification of a 50 kilobase deletion
106. A novel cystic fibrosis mutation involving the deletion of exons 14b through 18 (CF?20kbdel 14b-18) in a cystic fibrosis patient of German descent from Upstate New York
107. Population variation of common cystic fibrosis mutations
108. A novel donor splice site in intron 11 of the CFTR gene, created by mutation 1811+11.6kb A>G, produces a new exon: High frequency in spanish cystic fibrosis chromosomes and association with severe phenotype
109. Exon 9 the CFTR gene: Splice site haplotypes and cystic fibrosis mutations
110. Rapid characterization of the variable length polythymidine tract in the cystic fibrosis (CFTR) gene: Association of the 5T allele with selected CFTR mutations and its incidence in atypical sinopulmonary disease
111. Validation of double gradient denaturing gradient gel electrophoresis through multigenic retrospective analysis
112. Solid-phase fluorescent sequencing of the CFTR gene
113. Methods for detection of point mutations: Performance and quality assessment
114. Transcript analysis of CFTR frameshift mutations in lymphocytes using the reverse transcription-polymerase chain reaction technique and protein truncation test
115. A robotics-assisted procedure for large-scale cystic fibrosis mutation analysis
116. High throughput parallel analysis of hundreds of patient samples for more than 100 mutations in multiple disease genes
117. Robot printing of reverse dot blot arrays for human mutation detection
118. Development, multiplexing and application of ARMS tests for common mutations in the CFTR gene
119. Introduction to PCR/OLA/SCS, a multiplex DNA test and its application to cystic fibrosis
120. Analysis of 31 CFTR mutations by polymerase chain reaction/oligonucleotide ligation assay in a pilot screening of 4476 newborns for cystic fibrosis
121. Comprehensive and accurate mutation scanning of the CFTR gene by two-dimensional DNA electrophoresis
122. The ligase chain reaction in a PCR world
123. Minisequencing: A specific tool for DNA analysis and diagnostics on oligonucleotide arrays
124. A DNA microarray chip for mutation detection within cystic fibrosis transmembrane receptor gene (CFTR)
125. Cystic fibrosis mutation detection by hybridization to light-generated DNA probe arrays
126. II. Investigation of different PCR amplification systems in microfabricated silicon-glass chips
127. Detection of the deltaF508 (F508del) mutation of the cystic fibrosis gene by surface plasmon resonance and biosensor technology
128. An efficient protocol for CFTR mutation detection based on multiplex heterduplex analysis (mHET)
129. Slowly but surely towards better scanning for mutations
130. CF mutation analysis in Upstate New York
131. Two buffer PAGE system-based SSCP/HD analysis: A general protocol for rapid and sensitive mutation screening in cystic fibrosis and any other human genetic disease
132. Fluorescein-labeled oligonucleotides for real-time PCR: Using the inherent quenching of deoxyguanosine nucleotides
133. Clinical, genetic and pharmacogenetic applications of the Invader assay
134. Competitive oligonucleotide single-base extension combined with mass spectrometric detection for mutation screening
135. Rapid screening of genetic polymorphisms using buccal cell DNA with detection by matrix-assisted laser desorption/ ionization mass spectrometry
136. Abnormal distribution of cystic fibrosis delta F 508 allele in adults with chronic hypersectretion
137. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in allergic bronchopulmonary aspergillosis
138. Missense mutations in the cystic fibrosis gene in adult patients with asthma
139. CFTR gene variant IVS8-5T in disseminated bronchiectasis
140. Cystic fibrosis mutation screening in healthy men with reduced sperm quality
141. Heterogeneity of reproductive tract abnormalities in men with absence of the vas deferens: Role of cystic fibrosis transmemrane conductance regulator gene mutations
142. Cystic fibrosis mutation screening in CBAVD patients and men with obstructive azoospermia or severe oligozoospermia
143. Congenital unilateral absence of the vas deferens: A heterogeneous disorder with two distinct subpopulations based upon aetiology and mutational status of the cystic fibrosis gene
144. Increased incidence of cystic fibrosis gene mutations in adults with disseminated bronchiectasis
145. Mutation in the gene responsible for cystic fibrosis and predisposition to chronic Rhinosinusitis in the general population
146. CFTR gene mutations in adults with disseminated bronchiectasis
147. CFTR mutations and IVS8-5T variant in newborns with hypertrypsinaemia and normal sweat test
148. Cystic fibrosis gene mutations detected in hereditary pancreatitis
149. A specific cystic fibrosis mutation (T3381) associated with the phenotype of isolated hypotonic dehydration
150. Hypofertility with thick mucus: Another form of cystic fibrosis?
151. Relationship between mutations of the cystic fibrosis gene and idiopathic pancreatitis
152. Mutations of the cystic fibrosis gene in patients with chronic pancreatitis
153. Cystic fibrosis transmembrane conductance regulator gene mutations in severe nasal polyps
154. Abnormal frequency of ΔF508 mutation in neonatal transitory hypertrypsinaemia
155. Mutations in the cystic fibrosis transmembrane regulator gene in patients with tropical calcific pancreatitis